COMMUNIQUÉS West-GlobeNewswire

LogicBio Therapeutics Receives Rare Pediatric Disease Designation for LB-001 for the Treatment of Methylmalonic Acidemia
16/07/2019
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today [...]
Dave Kenney Certified as a Brain Health Coach by Amen Clinics
16/07/2019
Emergo Recovery Executive Director and CEO completes training on the Amen Clinics Method and cultivating brain health through neurobiology and practical neuroscience BARRIE, Ontario, July 16, 2019 (GLOBE NEWSWIRE) -- [...]
Mereo BioPharma Appoints Richard Francis as Head of Pharmaceutical Development
16/07/2019
LONDON and REDWOOD CITY, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), a clinical stage biopharmaceutical company focused on rare diseases, today announces the appointment [...]
Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
16/07/2019
Full enrollment expected to occur in calendar Q4 2019 CRANBURY, N.J., July 16, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused [...]
Alz1 Launches the First At-Home Solution to Detect, Help Reduce Risk Factor Associated with Alzheimer’s Disease
16/07/2019
The revolutionary Alz1 solution includes a convenient at-home blood test and dietary supplement to enable proactive healthcare MIAMI, July 16, 2019 (GLOBE NEWSWIRE) -- Alz1 , a brand of Igea Pharma focused on [...]
CareDx to Announce Second Quarter 2019 Financial Results on August 1, 2019
16/07/2019
BRISBANE, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value [...]
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
16/07/2019
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under [...]
ORYZON Presents Data From ETHERAL Phase IIa Trial at the 2019 Alzheimer's Association International Conference in Los Angeles
16/07/2019
ETHERAL has recruited more than 100 patients to date Safety data so far show that vafidemstat is safe and well tolerated Parametric functional evolution of the first (blinded) 33 patients that have been treated for 6 [...]
The New Hemp Energy Drink Will Soon Be Available In More Than 500 Stores in Quebec
16/07/2019
OTTAWA, ON, July 16, 2019 (GLOBE NEWSWIRE) -- Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (TSX VENTURE: TBP) (OTCQB: TBPMF), today announced that it has signed an agreement with Distribution AB inc. [...]
Le nouveau Hemp Energy Drink sera disponible dans plus de 500 points de vente au Québec
16/07/2019
OTTAWA, ON, 16 juill. 2019 (GLOBE NEWSWIRE) -- Tetra Santé Naturelle, une filiale de Tetra Bio-Pharma (TSX VENTURE: TBP) (OTCQB: TBPMF), annonce la conclusion d’une entente avec Distribution AB inc. pour la distribution [...]
MediWound to Host Analyst Day on its Innovative Product EscharEx® for Debridement of Chronic Wounds
16/07/2019
YAVNE, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will [...]
Eloxx Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on August 7, 2019
16/07/2019
Company management to host a webcast and conference call to provide a business update and review financial results at 8:30 a.m. ET WALTHAM, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: [...]
Spero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206
16/07/2019
CAMBRIDGE, Mass., July 16, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in [...]
Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseases
16/07/2019
Lead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020 SAN DIEGO, July 16, 2019 (GLOBE NEWSWIRE) -- Trefoil Therapeutics announced it raised $28 million in an [...]
Melinta Therapeutics Announces Preliminary Second Quarter 2019 Financial Results and Provides Corporate Update
16/07/2019
~ Expects to Report Second Quarter 2019 Net Product Sales of Approximately $13.8 Million, Which Represents an Increase of 17 Percent Over the First Quarter of 2019 ~ ~ Anticipates Having Approximately $90 Million of [...]
Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange
16/07/2019
The Company's shares, which currently trade on NASDAQ , will be dual-listed on the Tel Aviv Stock Exchange (TASE) starting on July 22, 2019, under the symbol ENLV Tel-Aviv, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- [...]
CURE Pharmaceutical [OTCQB:CURR] Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients
16/07/2019
OXNARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers [...]
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
16/07/2019
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the treatment of AML and MDS – SAN [...]
hATTR Compass™ Genetic Testing Program Continues to Expand and Enable Diagnosis and Treatment of Hereditary ATTR Amyloidosis One Year Following Launch
16/07/2019
Akcea and Ambry Genetics grow partnership, providing easily accessible, no-cost, confidential genetic testing and genetic counseling services to people with suspected hereditary ATTR amyloidosis BOSTON and Aliso Viejo, [...]

Pages